All GLP-1 receptor agonists developed from the human GLP-1 backbone (liraglutide, injectable semaglutide, albiglutide, and dulaglutide) are able to lower the risk for the composite outcome of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) [53,55,56,57]. Here, GLP1R is linked to myocardial infarction.